An interventional study of Magstim - rTMS system and Baseline Imaging and Questionnaires in Urinary Incontinence, Prostate Treatment and Incontinence After Prostate Treatment, sponsored by The Methodist Hospital Research Institute. Recruiting at 1 site in United States. Open to male participants aged 22 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by The Methodist Hospital Research Institute · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.
Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 194th largest by planned enrollment of the 249 interventional ones that give a count, is one of 11 that started in 2026, is one of 144 with no phase, reaches primary completion later than 32 of the 46 other live ones, and was the 293rd registered.
988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.
Browse Urinary Incontinence studies →33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 18+ · Women only
Duke University · Sites in United States
Ages 18+ · Men only
Ohio State University · Sites in United States
Ages 18+ · Women only
University of Miami · Sites in United States
Ages 18+ · Women only
VA Office of Research and Development · Sites in United States
Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.
This study: 22 Years to 80 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 23 · Phase 3 38 · Phase 4 35
First in 1993; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 23 is below the median of 66 across 743 interventional studies indexed under Urinary Incontinence.
Median enrollment 75 across the 249 interventional studies, 100 across the 43 observational. Of the 219 that completed or were terminated, 105 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 293 have an industry lead sponsor. The 10 most frequent:
The Methodist Hospital Research Institute is the lead sponsor of 162 studies on the registry; 61 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 18 (64%) have results posted.
The Methodist Hospital Research Institute has 3 studies filed under Urinary Incontinence — fewer than ten, so there is no comparison to draw.
16 of the studies in Urinary Incontinence with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT04565925The University of Texas Medical Branch, GalvestonSildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries | 2026-12-01 |
| NCT07534696University of California, Los AngelesEvaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy | 2026-12-31 |
| NCT06226220University of ChicagoPercutaneous Nerve Evaluation Trial Time | 2026-12-31 |
| NCT06369922University of RochesterTENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. | 2027-01-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 293 studies in Urinary Incontinence with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Incontinence after prostate treatment (IPT) affects up to 25% of men following radical prostatectomy or other prostate therapies, primarily resulting from sphincteric weakness and impaired neuromuscular control. Current management options, including behavioral therapy and surgical implants, are often limited by modest effectiveness or invasiveness. Emerging neuroimaging evidence demonstrates that the pelvic supplementary motor area (pSMA) in the brain plays a critical regulatory role in controlling pelvic floor muscles and urethral sphincter activity. This proof-of-concept, prospective, randomized clinical trial aims to evaluate the safety, tolerability, acceptability, and procedural feasibility of targeting the pSMA using non-invasive repetitive transcranial magnetic stimulation (rTMS) in adult males with IPT, alongside a cohort of continent controls. A total of 23 participants will be enrolled (targeting 10 evaluable IPT subjects and 10 continent controls). Participants undergo baseline fMRI using a natural bladder filling protocol, and a randomized, single-session neuronavigated rTMS protocol with concurrent pelvic floor electromyography (EMG) and functional Magnetic Resonance Imaging (fMRI) to evaluate physiological and neurofunctional changes. Safety and adverse events are monitored closely through a 1-month virtual follow-up visit. Findings from this study will establish foundational evidence for cortical modulation of pelvic floor control in IPT. Additionally, these results will guide the design of a future larger, clinical trial to optimize rTMS parameters and integrate brain neuromodulation into post-prostate treatment rehabilitation strategies.
Incontinence after prostate treatment (IPT) affects up to 25% of men following radical prostatectomy or other prostate therapies, primarily resulting from sphincteric weakness and impaired neuromuscular control. Current management options, including behavioral therapy and surgical implants, are often limited by modest effectiveness or invasiveness. Emerging neuroimaging evidence demonstrates that the pelvic supplementary motor area (pSMA) in the brain plays a critical regulatory role in controlling pelvic floor muscles and urethral sphincter activity. This proof-of-concept, prospective, randomized clinical trial aims to evaluate the safety, tolerability, acceptability, and procedural feasibility of targeting the pSMA using non-invasive repetitive transcranial magnetic stimulation (rTMS) in adult males with IPT, alongside a cohort of continent controls. A total of 23 participants will be enrolled (targeting 10 evaluable IPT subjects and 10 continent controls). Participants undergo baseline fMRI using a natural bladder filling protocol, and a randomized, single-session neuronavigated rTMS protocol with concurrent pelvic floor electromyography (EMG) and functional Magnetic Resonance Imaging (fMRI) to evaluate physiological and neurofunctional changes. Safety and adverse events are monitored closely through a 1-month virtual follow-up visit. Findings from this study will establish foundational evidence for cortical modulation of pelvic floor control in IPT. Additionally, these results will guide the design of a future larger, clinical trial to optimize rTMS parameters and integrate brain neuromodulation into post-prostate treatment rehabilitation strategies. Study Objectives: Aim 1: Assess the safety, tolerability, acceptability (measured via the Acceptability of Intervention Measure [AIM] questionnaire), and procedural feasibility of performing pSMA-targeted rTMS, concurrent pelvic floor electromyography (EMG), and functional Magnetic Resonance Imaging (fMRI) in men with IPT. Aim 2: Evaluate the physiological and neurofunctional effects of excitatory (high-frequency) and inhibitory (low-frequency) rTMS on pSMA activity (assessed via BOLD signal changes on fMRI) and pelvic floor muscle tone (assessed via EMG amplitudes). Aim 3: Compare baseline pSMA activity (BOLD signal on fMRI) and functional connectivity during natural bladder filling between continent post-prostate-treatment controls and men with IPT. Study Design \& Procedures:
This single-center, prospective, randomized trial enrolls 23 participants (10 IPT subjects and 10 continent controls evaluable). Participants attend up to 5 scheduled visits over 6 to 8 weeks (4 to 6 weeks for controls): Visits 1 \& 2 (Screening \& Baseline): Informed consent, cognitive assessment (MoCA), medical history, baseline urological questionnaires (AUA-SS, ICIQ-UI SF), bladder diaries, and baseline diagnostics (uroflow, PVR, urinalysis). Visit 3 (Baseline Imaging): Anatomical and functional brain MRI (3T or 7T) with a natural bladder filling protocol to map pSMA coordinates. For continent controls, study participation concludes after Visit 3. Visit 4 (Intervention \& Post-Scan - IPT Cohort Only): Randomization 1:1 to either high-frequency (Arm 1) or low-frequency (Arm 2) rTMS delivered via the Magstim Rapid2 system and neuronavigation. Perineal EMG records muscle activity during standardized Kegel exercises, followed immediately by post-intervention fMRI and the AIM acceptability questionnaire. Visit 5 (Follow-Up - IPT Cohort Only): A 1-month virtual safety check-in to monitor for delayed adverse events. Study Endpoints: Primary Endpoints: Recruitment/retention rates, participant acceptability (AIM scores), and incidence/severity of adverse events. Secondary Endpoints: Changes in BOLD signal activity and EMG amplitudes following rTMS, and baseline functional connectivity differences between IPT subjects and continent controls.
Inclusion Criteria (IPT Cohort):
Inclusion Criteria (Continent Control):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive high-frequency (excitatory) repetitive transcranial magnetic stimulation (rTMS) targeted at the pelvic supplementary motor area (pSMA) for 20 minutes total.
Device: Magstim - rTMS system
Participants receive low-frequency (inhibitory) repetitive transcranial magnetic stimulation (rTMS) targeted at the pelvic supplementary motor area (pSMA) for 20 minutes.
Device: Magstim - rTMS system
Non-interventional Control Group undergoing questionnaires and baseline imaging (fMRI)
Other: Baseline Imaging and Questionnaires
The Magstim Rapid2 system is a magnetic stimulation system capable of selectively inducing, modulating, or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS. Utilizing the StimGuide navigation system, the investigators will accurately target the pelvic supplementary motor area (pSMA). The Magstim Rapid2 system is used in this study to deliver either high-frequency (excitatory) or low-frequency (inhibitory) rTMS to assess physiological and neurofunctional effects on continence control in men with incontinence after prostate treatment (IPT).
Non-interventional control consistent of questionnaires and baseline brain functional MRI (fMRI) with no rTMS stimulation.
Recruitment and Retention Rate
Evaluation of study feasibility by tracking the proportion of participants successfully enrolled in the study compared to those lost to follow-up or withdrawn prior to completion.
Time frame: From enrollment through the 1-month follow-up visit (approximately 2 to 3 months total per participant)
Acceptability of Intervention
Participant acceptability, feasibility, and practicality evaluated using the Acceptability of Intervention Measure (AIM) questionnaire.
Time frame: Immediately after the single rTMS treatment session (Visit 4 : 3 weeks +/- 2 weeks after enrollment)
Adverse Events
The incidence of all patient- or physician-reported adverse events (AEs) related to the procedure, device, and/or stimulation occurring throughout the study duration.
Time frame: From informed consent through the 1-month virtual follow-up visit
pSMA Activity
Changes in blood-oxygen-level-dependent (BOLD) signals within the pelvic supplementary motor area (pSMA) assessed via functional MRI between baseline and post-treatment scans.
Time frame: Baseline (Visit 3) and post rTMS treatment fMRI on the day of rTMS session (Visit 4: 3 weeks +/- 2 weeks after enrollment)
Pelvic Floor Muscle Tone
Changes in pelvic floor muscle (PFM) tone assessed via perineal surface electromyography (EMG) amplitudes recorded at rest, during standardized Kegel exercises, and after each corresponding rTMS pulse train.
Time frame: During the 20-minute rTMS treatment session (Visit 4 : 3 weeks +/- 2 weeks after enrollment)
Baseline Functional Connectivity
Differences in baseline pSMA BOLD signal and functional connectivity during natural bladder filling between men with incontinence after prostate treatment (IPT) and continent controls (CC).
Time frame: Baseline imaging session (Visit 3)
PDFs hosted by the registry, ClinicalTrials.gov.
Started Sep 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.
Of 303 non-industry interventional studies with no phase under Urinary Incontinence, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 12 months is below that.
Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Methodist Hospital Research Institute →